Merck Passes Huntington’s RNAi Program To Targeted Genetics
This article was originally published in The Pink Sheet Daily
Executive Summary
Sirna division’s early-stage targets are of lesser interest to the pharma firm, analyst tells “The Pink Sheet” DAILY.
You may also be interested in...
Clinical Stage Biotechs For Sale?
The oversized price tag attached to the recent acquisition of Pharmasset by Gilead has caused many to wonder how the take-out fits into historical patterns – or if it’s as big an outlier as it seems.
Prestwick’s Xenazine For Huntington’s Chorea Gets Positive Vote From FDA Panel
FDA’s Peripheral and CNS Drug advisory panel votes unanimously that adverse events associated with the Huntington’s disease treatment do not trump the drug’s proven efficacy.
Amarin Plans Additional Phase III Trial For Miraxion To Support Huntington's NDA
London firm aims to substantiate the effectiveness of the neuroprotector in a genetic subgroup of Huntington's patients.